Health
Personalized skin cancer vaccine reduces risk of recurrence or death
Phase 3 clinical trial indicates that mRNA-based therapy combined with immunotherapy decreased the relative risk of disease return or death by 42%, but the treatment remains investigational.
You have used your 3 free reads for today
The full text of this story becomes available after the daily renewal. Sports and entertainment stay open. The paid subscription is not open yet.
Your free reads renew on 11/15/2026 at 00:00 (Brasília time).
The essentials of this story
- What happened
- A therapeutic vaccine combined with immunotherapy reduced the relative risk of melanoma recurrence or death by 42% in a phase 3 study.
- Who is affected
- Patients with cutaneous melanoma in stages IIB to IV who underwent surgical tumor removal.
- What changes
- Personalized mRNA therapy combined with Keytruda demonstrates superior efficacy against tumor recurrence compared to the isolated use of the drug, although the treatment remains investigational and without regulatory approval.
Create a free account to keep reading: 3 full stories a day.
The paid subscription is not on sale yet. Free sign-up already works. Planned monthly price: R$ 9.90 (in US dollars and euros, a direct conversion at the official rate on the day you subscribe).